Panel Discussion: Unearthing Strategies to Define & Measure Treg Modulation

• Defining effective Treg modulation to develop a standardized measurement of efficacy beyond the number of Tregs
• Evaluating genomic screening, cytokine measurement, Treg biology and tissue samples to identify the most effective strategy to measure Treg efficacy
• Highlighting the endpoint and efficacy criteria required for regulatory approval
• Discussing the translatability of preclinical mouse model biomarkers to patients

Speakers:

Marc Martinez-Llordella

Co-founder and Vice President Biology

Quell Therapeutics

Joanne Tan

Sr Vice President R&D

Parvus Therapeutics

Eun Mi Hur

Scientific Director

Bristol Myers Squibb